Registered number: 11085607

CELEX ONCOLOGY INNOVATIONS LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2023

CELEX ONCOLOGY INNOVATIONS LIMITED
REGISTERED NUMBER: 11085607

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

			2023		2022
			£		£
Fixed assets					
Intangible assets	4		**700,251**		*605,507*
			700,251		*605,507*
Current assets					
Debtors: amounts falling due within one year	5	**28,343**		*3,454*	
Cash at bank and in hand	6	**128,201**		*411,609*	
		156,544		*415,063*	
Creditors: amounts falling due within one year	7	**(67,827)**		*(188,888)*	
Net current assets			**88,717**		*226,175*
Total assets less current liabilities			**788,968**		*831,682*
Net assets			**788,968**		*831,682*
Capital and reserves					
Called up share capital	8		**424**		*424*
Share premium account			**874,513**		*874,513*
Profit and loss account			**(85,969)**		*(43,255)*
			788,968		*831,682*

STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

L J Cohen
Director

Date: 17 December 2024

The notes on pages 3 to 5 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1. General information

Celex Oncology Innovations Limited is a private company limited by shares and incorporated in England. The registered office is 101 New Cavendish Street,1st Floor South, London, United Kingdom,W1W 6XH.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

2.2 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.3 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Amortisation will only commence once commercial production has started or when the developed product or service comes into use.

2.4 Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.5 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.6 Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

3. Employees

The average monthly number of employees, including directors, during the year was 3 *(2022 - 3)*.

4. Intangible assets

	Patents
	£
Cost	
At 1 January 2023	**605,507**
Additions	**94,744**
At 31 December 2023	**700,251**
Net book value	
At 31 December 2023	**700,251**
At 31 December 2022	*605,507*

5. Debtors

	2023	*2022*
	£	*£*
Other debtors	**3,827**	*3,454*
Prepayments and accrued income	**24,516**	-
	28,343	*3,454*

6. Cash and cash equivalents

	2023	*2022*
	£	*£*
Cash at bank and in hand	**128,201**	*411,609*
	128,201	*411,609*

7. Creditors: Amounts falling due within one year

	2023	2022
	£	£
Trade creditors	**9,688**	*10,856*
Amounts owed to other participating interests	**-**	*121,370*
Other creditors	**54,864**	*54,862*
Accruals and deferred income	**3,275**	*1,800*
	67,827	*188,888*

8. Share capital

	2023	2022
	£	£
Allotted, called up and fully paid		
4,241,457 *(2022 - 4,241,457)* Ordinary shares of £0.0001 each	**424.15**	*424.15*

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.